AMR101
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $7,187 | 3 | 0 |
| 2019 | $1.6M | 178 | 2 |
| 2018 | $2.8M | 402 | 11 |
| 2017 | $3.7M | 635 | 12 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $8.1M | 1,218 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the effect of AMR101 on Cardiovascular Heath and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardio | Amarin Pharma Inc. | $6.9M | 12 |
| Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin Therapy | Amarin Pharma Inc. | $733,198 | 0 |
| Vascepa to Accelerate Lipoprotein Uptake and Elimination (The VALUE Study): An Open-Label, Mechanistic, Randomized, Controlled, Single-Center, Adaptive-Design Trial of Icosapent Ethyl Oil in Dyslipidemic Patients | Amarin Pharma Inc. | $323,651 | 0 |
| Association of DNA Sequence Varients in EPA Genes with Coronary Artery Disease | Amarin Pharma Inc. | $110,038 | 0 |
| Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid (BRAVE-EPA) | Amarin Pharma Inc. | $5,937 | 0 |
Top Doctors Receiving Payments for AMR101
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Omaha, NE | $7.5M | 1,062 |
| , MD | Cardiovascular Disease | Westwood, MA | $151,882 | 26 |
| , MD | Internal Medicine | Boston, MA | $108,344 | 21 |
| , M.D | Internal Medicine | Boston, MA | $94,890 | 21 |
| , M.D | Cardiovascular Disease | Atlanta, GA | $87,004 | 23 |
| , M.D | Neurology | Coopersburg, PA | $46,170 | 20 |
| Anjan Chakrabarti | Internal Medicine | Virginia Beach, VA | $37,891 | 15 |
| , M.D | Interventional Cardiology | Natick, MA | $28,680 | 6 |
| , MD | Internal Medicine | Iowa City, IA | $16,101 | 8 |
| , MD | Endocrinology, Diabetes & Metabolism | Salt Lake City, UT | $12,150 | 4 |
| , M.D | Cardiovascular Disease | Baltimore, MD | $11,360 | 6 |
| , M.D | Cardiovascular Disease | Cleveland, OH | $1,760 | 1 |
| , MD | Internal Medicine | Houston, TX | $1,500 | 5 |
Manufacturing Companies
- Amarin Pharma Inc. $8.1M
Product Information
- Type Drug
- Total Payments $8.1M
- Total Doctors 12
- Transactions 1,218
About AMR101
AMR101 is a drug associated with $8.1M in payments to 12 healthcare providers, recorded across 1,218 transactions in the CMS Open Payments database. The primary manufacturer is Amarin Pharma Inc..
Payment data is available from 2017 to 2020. In 2020, $7,187 was paid across 3 transactions to 0 doctors.
The most common payment nature for AMR101 is "Unspecified" ($8.1M, 100.0% of total).
AMR101 is associated with 5 research studies, including "A Multi-Center, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the effect of AMR101 on Cardiovascular Heath and Mortality in Hypertriglyceridemic Patients with Cardiovascular Disease or at High Risk for Cardio" ($6.9M).